Cogent Biosciences, Inc. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report; separate Q4 financial results are not provided in the filing text.
Business context
Cogent is a clinical-stage biotechnology company developing precision medicines for genetically defined diseases. Its lead candidate, bezuclastinib, is being studied for systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Earlier-stage programs target FGFR2, ErbB2 and PI3Kα. The company had no approved products and generated no product-sales revenue.
Financial and liquidity summary
| Metric | FY 2023 / Dec. 31, 2023 | FY 2022 / Dec. 31, 2022 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $173.8 million | $121.6 million |
| General and administrative expense | $34.4 million | $26.2 million |
| Total operating expenses | $208.1 million | $147.8 million |
| Net loss | $192.4 million | $140.2 million |
| Net loss per share, basic and diluted | $2.42 | $2.39 |
| Net cash used in operating activities | $153.6 million | $118.6 million |
| Cash, cash equivalents and marketable securities | $273.2 million | $259.3 million |
| Total assets | $313.4 million | $300.8 million |
| Total liabilities | $55.6 million | $45.1 million |
- R&D expense rose $52.1 million, primarily from bezuclastinib trials and manufacturing, pipeline research, higher personnel costs and research-facility expenses. G&A expense increased $8.2 million, primarily due to personnel costs.
- Interest income increased to $13.1 million from $4.0 million, reflecting higher average invested balances and interest rates. Other income included a $1.7 million reduction in the CVR liability; the CVRs expired in August 2023 with no further payments due.
- Cash and marketable securities were $273.2 million at year-end. Current assets were $270.8 million versus current liabilities of $38.2 million. The company reported $18.9 million of operating lease liabilities; the filing does not report financial borrowings.
- Financing activities provided $163.5 million in 2023, mainly from a June public offering that generated approximately $161.8 million net proceeds. In February 2024, after year-end, a private placement raised $225 million gross. Management estimates year-end liquidity plus those proceeds will fund operations and capital expenditures into 2027 and through anticipated readouts from the registration-directed SUMMIT, PEAK and APEX trials; this estimate depends on assumptions and is not assured.
- Profit margins are not meaningful for this pre-revenue company. The filing reports net losses since inception and an accumulated deficit of $603.6 million at year-end.
Clinical progress, outlook and material risks
- SUMMIT (Non-AdvSM, Phase 2): Part 1 enrollment completed in 2023. Part 2 is planned for 159 patients, with enrollment expected to finish in Q2 2025 and top-line results by year-end 2025. In Part 1b, 100 mg once daily was selected for Part 2. Reported 12-week results included improvements in symptom and quality-of-life measures and disease biomarkers versus placebo. These results came from a small early-stage cohort; the primary endpoint depends on FDA alignment on the company-developed symptom diary.
- APEX (AdvSM, Phase 2): Part 1 reported a 52% objective response rate among 27 evaluable patients under modified response criteria; response was 75% under pure pathological response criteria. The registration-directed study was expected to complete enrollment by year-end 2024, with top-line results expected by mid-2025. The filing reported related serious adverse events, dose reductions and discontinuations in Part 1.
- PEAK (GIST, Phase 3): The randomized trial compares bezuclastinib plus sunitinib with sunitinib alone after imatinib. The company expected enrollment completion by year-end 2024 and top-line results by year-end 2025. Lead-in data were encouraging, but progression-free-survival data were immature; reported response results are from limited patient subsets.
- Research pipeline: CGT4859 was selected as an FGFR2 clinical candidate, with a Phase 1 trial expected in 2024. The company expected to select an ErbB2 candidate in 2024 and advance the PI3Kα program toward candidate selection and IND-enabling work. Supporting results disclosed were preclinical, not clinical.
- Management expects substantial ongoing spending and operating losses. Additional funding may be needed; equity or convertible financing could dilute shareholders, while debt or partnerships could impose restrictions or require relinquishing rights.
- Key risks include clinical or regulatory failure, small trial populations and changing preliminary data, patient-enrollment delays, adverse effects, competition, uncertain market size and reimbursement, and reliance on third parties. Bezuclastinib API and drug product are supplied by single-source vendors, and the company has no long-term supply arrangements or validated commercial manufacturing process.
- The company has no material legal proceedings. PwC issued an unqualified audit opinion and concluded that internal control over financial reporting was effective as of December 31, 2023.
Most important facts for investors to verify
- Whether the pivotal or registration-directed SUMMIT, PEAK and APEX trials enroll on schedule, meet agreed endpoints and confirm efficacy and safety in larger populations.
- Whether management’s runway estimate through 2027 remains credible as trial costs, operating expenses and cash burn evolve; distinguish year-end liquidity from the subsequent $225 million gross financing.
- The net proceeds, dilution and conversion conditions of the February 2024 private placement, including the required shareholder approval to increase authorized common shares.
- FDA alignment on the SUMMIT symptom endpoint, and whether safety findings—including liver-enzyme events and other serious adverse events—affect dose, trial design or development timelines.
- Progress toward backup manufacturing suppliers, commercial-scale processes and intellectual-property protection for bezuclastinib and the newer pipeline candidates.